Drugs Made In America Acquisition Corp. (DMAAR) Other Working Capital Changes (2025)
Drugs Made In America Acquisition's (DMAAR) quarterly Other Working Capital Changes came in at -$21425.0 in Q4 2025, little changed quarter-over-quarter from -$21425.0 in Q3 2025.
Powered by 
Analysis
Drugs Made In America Acquisition Corp. (DMAAR) Other Working Capital Changes (2025) Analysis & Trends
Drugs Made In America Acquisition (DMAAR) has reported Other Working Capital Changes for 1 consecutive years, with -$21425.0 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Other Working Capital Changes changed N/A year-over-year to -$21425.0; the trailing twelve-month figure through Dec 2025 stood at $6054.0 (changed N/A YoY), and the FY2025 full-year result was $6054.0, changed N/A from the prior year.
- Other Working Capital Changes was little changed at -$21425.0 in Q4 2025 per DMAAR's latest filing, from -$21425.0 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $70096.0 in Q1 2025 and bottomed at -$21425.0 in Q3 2025.
Peer Set
Peer Comparison
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -21,425.00 |
| Dec 31, 2025 | -21,425.00 |
| Sep 30, 2025 | -21,425.00 |
| Sep 30, 2025 | -21,425.00 |
| Jun 30, 2025 | -21,192.00 |
| Jun 30, 2025 | -21,192.00 |
| Mar 31, 2025 | 70,096.00 |
| Mar 31, 2025 | 70,096.00 |